A new Flag­ship start­up looks to crack tR­NA bi­ol­o­gy in search for com­plete­ly new class of ther­a­peu­tics

With Mod­er­na and its mR­NA-based vac­cine act­ing as a proof of con­cept, Flag­ship Pi­o­neer­ing has dived head­first in­to tap­ping oth­er forms of RNA as po­ten­tial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER